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STATE-OF-THE-ART PAPER STATE-OF-THE-ART PAPER1339Risks and Benefits of Anticoagulation for Patients With AF and Renal DiseaseRicarda Marinigh, Deirdre A. Lane, Gregory Y. H. Lip
Most studies have found that renal impairment increases the risk of stroke in patients
with atrial fibrillation (AF); however, current stroke risk stratification schemes are based
on studies that deliberately excluded patients with severe renal impairment. There are
no large randomized controlled trials that assess the real risk/benefit of full intensity
anticoagulation in patients with severe renal impairment. Marinigh and colleagues review
the available data on this issue as well as data that indicate there are higher rates of
major bleeding episodes in anticoagulated hemodialysis patients.CLINICAL RESEARCH INTERVENTIONAL CARDIOLOGY1349Incidence and Prognosis of Patients With Left Main RestenosisJong-Young Lee, Duk-Woo Park, Young-Hak Kim, Sung-Cheol Yun, Won-Jang Kim, Soo-Jin Kang,
Seung-Whan Lee, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Lee and colleagues evaluated the incidence, predictors, and long-term outcomes of
patients with in-stent restenosis (ISR) with drug-eluting stents (DES) for unprotected
left main coronary artery (ULMCA) disease. A total of 509 consecutive patients with
ULMCA disease underwent DES implantation during the study period, and 80%
underwent routine surveillance or clinically-driven angiographic follow-up. The overall
incidence of angiographic ISR in ULMCA lesions was 18%. Fifty-six percent of patients
underwent repeat PCI, 14% underwent bypass surgery, and 30% were treated medically.
During follow-up, there were no deaths, there was 1 myocardial infarction, and 9% of
patients had repeated target lesion revascularization. The long-term clinical prognosis of
patients with DES-ISR associated with ULMCA stenting might be benign.(continued on page A-22)
MARCH 22, 2011 (continued) A-22MYOCARDIAL INFARCTION1359Coronary Thrombus Composition Changes During Acute MIJohanne Silvain, Jean-Philippe Collet, Chandrasekaran Nagaswami, Farzin Beygui, Kathryn E. Edmondson,
Anne Bellemain-Appaix, Guillaume Cayla, Ana Pena, Delphine Brugier, Olivier Barthelemy,
Gilles Montalescot, John W. Weisel
Thrombus aspiration from patients undergoing percutaneous coronary intervention
allowed Silvain and colleagues to study the composition of occlusive thrombi in
ST-segment elevation myocardial infarction (MI) patients. Intracoronary thrombi were
obtained by thromboaspiration and analyzed with a scanning electron microscope. Thrombi
were mainly composed of fibrin (56%) with platelets (17%), erythrocytes (11%), and
cholesterol crystals (5%). Fibrin content increased with ischemic time, while platelet content
decreased. The changing composition of occlusive thrombus over time may have a direct
impact on the efficacy of drugs or devices used for coronary reperfusion.DIASTOLIC FUNCTION1368Obesity Independently Related to Diastolic DysfunctionCesare Russo, Zhezhen Jin, Shunichi Homma, Tatjana Rundek, Mitchell S. V. Elkind, Ralph L. Sacco,
Marco R. Di Tullio
Russo and colleagues evaluated the relationship between body size and left ventricular (LV)
diastolic function, which might be the link between obesity and an increased risk of heart
failure. LV diastolic function was evaluated in 950 participants by traditional and tissue
Doppler imaging. Overweight and obese subjects had lower E’, lower E/A, and higher E/E’
than normal-weight participants. Increased body mass index is associated with worse LV
diastolic function independent of LV mass and associated risk factors.HEART FAILURE1375Long-Term Benefit of an Intrapericardial Left Ventricular Assist SystemMartin Strueber, Gerry O’Driscoll, Paul Jansz, Asghar Khaghani, Wayne C. Levy, George M. Wieselthaler,
for the HeartWare Investigators
The HeartWare Ventricular Assist System (HeartWare, Inc., Framingham, Massachusetts) is
a new mechanical circulatory support system that is smaller and more durable than previous
left ventricular assist device systems. This report describes the initial long-term outcomes in
heart transplant candidates supported for at least 180 days, until heart transplant, myocardial
recovery and device explant, or death. Of the 50 patients, 40% received heart transplants, 8%
had the HeartWare Ventricular Assist Device pump explanted after recovery of myocardial
function, and 34% continued support past 2 years. The survival rates at 6, 12, and 24 months
were 90%, 85%, and 82%, respectively. Patients with end-stage heart failure can be safely and
effectively supported by the HeartWare Ventricular Assist System.
Editorial Comment: Salpy V. Pamboukian, p. 1383(continued on page A-24)
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hBIOMARKERS1386ProBNP Circulates in the General Community1–108
Fima Macheret, Guido Boerrigter, Paul McKie, Lisa Costello-Boerrigter, Brian Lahr, Denise Heublein,
Sharon Sandberg, Yasuhiro Ikeda, Alessandro Cataliotti, Kent Bailey, Richard Rodeheffer, John C. Burnett, Jr
The current concept for cardiac endocrine function is that in response to cardiac stress the
heart secretes B-type natriuretic peptide (BNP1–32) and amino-terminal proBNP
NT-proBNP1–76) after intracardiac cleavage of their molecular precursor, proBNP1–108.
acheret and colleagues used a novel assay to determine if proBNP1–108 circulates in normal
uman subjects. Circulating proBNP1–108 levels in normal humans were strongly influenced
by sex, age, heart rate, and body mass index. The median concentration was 20 ng/l. The
proBNP1–108/NT-proBNP1–76 ratio of 0.366 decreased with heart failure (HF) stage. These
findings may provide insights into altered proBNP1–108 processing during HF progression.Editorial Comment: Michele Emdin, Claudio Passino, Aldo Clerico, p. 1396
